PacBio en­gi­neers $800M buy­out of se­quenc­ing ri­val Om­niome as an­a­lysts fret over FTC ac­tion

As Il­lu­mi­na runs in­to an­oth­er reg­u­la­to­ry road­block to ex­pan­sion, one of its al­most-sub­sidiaries is charg­ing ahead with a new buy­out.

Pa­cif­ic Bio­sciences, of­ten re­ferred to as PacBio, is aim­ing to swal­low ri­val Om­niome in an $800 mil­lion stock and cash deal, the com­pa­nies an­nounced Tues­day morn­ing. PacBio will fork over $600 mil­lion up­front con­sist­ing of $300 mil­lion cash and 9.4 mil­lion shares, and is on the hook for an­oth­er $200 mil­lion in cash and stock should cer­tain mile­stones be achieved.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters